Persistent and Latent Viral Infections

Persistent viral infections fall into distinct patterns of true latency, chronic active replication, or a combination of both.

Persistence is a general term for any infection not fully cleared by the host immune response, continuing in some form for a prolonged period, potentially the remainder of the host's life. Latency is one specific subtype of persistence. Persistence also includes infections with ongoing, chronic active viral replication that never become latent in the strict sense.

Latency is a specific form of persistence defined by transcriptional silence. The viral genome remains present within host cells but produces no, or minimal, viral protein and no infectious virions. This renders the infected cell essentially invisible to both antibody and cytotoxic T cell surveillance, while retaining the capacity to reactivate.

Reactivation is the re-emergence of active viral gene expression and replication from a previously latent state. It is typically triggered by a decline in host immune surveillance or, for some viruses, other specific local or systemic triggers.

Chronic replication is ongoing, active viral replication that is never fully suppressed by the host immune response but also never becomes transcriptionally silent in the way latency requires.

The infected host remains persistently viraemic or, for HBV specifically, persistently produces detectable viral antigen and DNA. This is a genuinely different biological state from latency, despite both being forms of persistence.

Latent viruses are periodically silent and periodically active. They reactivate intermittently, often triggered by identifiable immune or physiological stress. Active disease and shedding are confined to these reactivation episodes, and the intervening periods are genuinely free of viral protein production.

Chronically replicating, persistent but non-latent viruses are continuously active. The host immune response contains but never eliminates or silences ongoing replication. Some degree of viral replication and potential infectiousness is present essentially throughout the entire infection, not confined to discrete reactivation episodes.

This distinction is the single most important organising concept in this topic, and directly explains why the two groups of organisms are managed so differently in clinical practice.

Latent infections are managed by treating reactivation episodes as they occur and, for some, by suppressive therapy specifically to reduce reactivation frequency.

Chronically replicating persistent infections require ongoing, continuous antiviral suppression or, for HCV specifically, a genuinely curative treatment course. This controls ongoing active replication that would otherwise continue indefinitely, without any natural quiescent phase to rely on.

HSV. Latency is established in sensory ganglia, trigeminal for orolabial HSV-1 and sacral for genital HSV-2, following primary mucocutaneous infection. Reactivation, triggered by stress, UV exposure, fever, immunosuppression or local trauma, produces recurrent mucocutaneous lesions.

Between reactivation episodes, the virus is genuinely transcriptionally silent. Only a small number of latency-associated transcripts are expressed, none of which produce infectious virions.

VZV. Latency is established in dorsal root and cranial nerve sensory ganglia following primary varicella. Reactivation, herpes zoster, occurs, often after decades. Risk increases substantially with age and immunosuppression, reflecting gradual decline in the cell-mediated immune surveillance that normally maintains latency.

EBV. Latency is established specifically in B lymphocytes, with the viral genome persisting as an episome and only a restricted subset of latency genes expressed.

Distinctively among the latent herpesviruses, EBV also maintains a low level of ongoing, generally asymptomatic viral shedding in saliva throughout life, even without overt clinical reactivation. The distinction between latency and reactivation is therefore not always absolute at the population level, even when it remains clinically meaningful for the individual patient.

CMV. Latency is established in myeloid lineage cells, monocytes and precursors. Reactivation, producing clinically significant end-organ disease, occurs particularly with significant immunosuppression, in transplant recipients and advanced HIV. Donor-recipient CMV serostatus mismatch specifically informs post-transplant prophylaxis strategy.

HIV is the paradigm example of a virus achieving both patterns simultaneously in different cellular compartments. Chronic active replication in productively infected CD4 T cells drives progressive immune destruction. It coexists with a genuine latent reservoir within long-lived resting memory CD4 T cells, in which the integrated provirus remains transcriptionally silent.

Antiretroviral therapy fully suppresses the chronically replicating, actively producing viral population to undetectable levels in blood. Because of the dual pattern, it cannot eliminate the latent proviral reservoir, and treatment interruption reliably results in viral rebound from this latent compartment. This is the central obstacle to HIV cure.

HBV. Chronic infection, defined by persistence of HBsAg beyond six months, involves ongoing, chronic active viral replication. The degree of replication, and the corresponding infectivity and disease activity, fluctuates over the natural history of chronic infection.

The recognised phases are high-replication and immune-tolerant, immune-active, and low-replication and inactive carrier. In some patients, HBeAg-negative chronic hepatitis reflects the precore mutant pattern.

This occurs without the genome-wide transcriptional silence that defines true latency in the herpesvirus sense.

HBV covalently closed circular DNA, cccDNA, is a stable episomal form of the viral genome persisting within the infected hepatocyte nucleus. It is the specific molecular reservoir responsible for the very low but genuine rate of true cure achieved even with effective, prolonged antiviral suppressive therapy. It conceptually parallels, though is mechanistically distinct from, HIV's latent proviral reservoir as the specific barrier to cure.

HCV. Chronic infection involves ongoing, continuous active viral replication, and the majority of infections progress to chronicity. There is no latent phase at all, which distinguishes HCV's persistence pattern from both HIV's dual latent and chronic-active pattern and HBV's cccDNA-based reservoir.

This absence of a true latent reservoir is a major reason HCV, unlike HIV and HBV, is genuinely curable with a finite course of direct-acting antiviral therapy. There is no dormant, drug-invisible viral compartment, analogous to HIV's latent CD4 reservoir or HBV's cccDNA, for the virus to persist within once active replication has been fully suppressed for a sufficient duration.